Multivariable Radiomics Model for Predicting Programmed Death‐Ligand 1 Expression After Neoadjuvant Chemoradiotherapy in Esophageal Squamous Cell Carcinoma

Beyond Major Pathologic Response in Lung Cancer: Biomarkers Predict Outcomes.

Neoadjuvant chemoimmunotherapy improves outcomes in resectable non-small cell lung cancer, yet pathologic response incompletely predicts durability of benefit. Spatial profiling using resected tumors and lymph nodes revealed distinct immune subtypes and identified a gene signature associated with improved outcomes, pro...

Gene-expression profiling to predict the risk of locoregional recurrence in breast cancer

Risk Prediction Models for Recurrence After Curative Treatment of Early‐Stage or Locally Advanced Lung Cancer: A Systematic Review

Lung cancer remains the leading cause of cancer‐related mortality worldwide. Despite advances in treatment, postoperative recurrence rates in early‐stage and locally advanced non‐small cell lung cancer (NSCLC) remain substantial. Prognostic models may support risk stratification and guide posttreatment management.

Real‐World Outcomes of Weekly Paclitaxel–Carboplatin‐Based Chemoradiotherapy Versus Cisplatin‐Based Chemoradiotherapy for FIGO Stage IB2–IVA Cervical cancer: A Retrospective Observational Study

We compared outcomes and toxicities of weekly paclitaxel plus carboplatin‐based (wTC) and cisplatin‐based (CDDP) concurrent chemoradiotherapy (CCRT) in FIGO stage IB2–IVA cervical cancer cases.

Integrating Molecular Classification Based on FGFR3, KRAS, HRAS, and TP53 Mutation With TNM Staging Modestly Improves Prediction of Prognosis of Upper Tract Urothelial Carcinoma After Surgery

To evaluate whether a simplified mutation‐based classification using archival formalin‐fixed paraffin‐embedded (FFPE) specimens provides prognostic information beyond pathological stage in patients with upper tract urothelial carcinoma (UTUC) undergoing nephroureterectomy.

First‐Line PD‐1 Inhibitor‐Based Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Revised Systematic Review and Meta‐Analysis of Phase III Trials

Immune checkpoint blockade has changed the first‐line treatment landscape for advanced esophageal squamous cell carcinoma (ESCC), but the magnitude and consistency of benefit across phase III trials require careful synthesis.